The 786-O cell line, selected for its abundant PLOD2 expression and tumorigenic competence (Fig. S6), was subcutaneously injected into the NOD/Scid mice to form the PLOD2-rich ccRCC xenografts. This evidence concerns the gene PLOD2 and nonpapillary renal cell carcinoma.